Amundi Eastc Xr Regulatory News (EAST)

29 Mar 2019 12:17

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF THAT JURISDICTION

Certain information contained within this Announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (“MAR”). Upon publication of this Announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain. The Company confirms that it currently has no unpublished price sensitive information.

EASTPHARMA LTD

(“the Company” or “Eastpharma”)

EASTPHARMA’S DELISTING OF ITS GDRS

As earlier reported at: https://www.eastpharma.com, the delisting of the Company’s global depositary shares (“GDRs”) listed on the London Stock Exchange was approved by the Board of Directors. The Company will today apply to the (i) United Kingdom Listing Authority to cancel the listing of GDRs from the Official List; and (ii) London Stock Exchange (“LSE”) to cancel the admission to trading of the GDRs on the Main Market of the LSE. In accordance with UK Listing Rule 5.2.8, the Company is required to give at least 20 business days' notice of its LSE delisting, which is therefore expected to take effect at 8.00 a.m. (London time) on 1 May 2019.

The Regulation S GDRs to be delisted trade under the symbol EAST on the LSE ISIN: US27778Q2049 and the 144A GDRs to be delisted trade under symbol 63PE ISIN: US27778Q1058.

It is the Company’s intention to delist both Regulations S GDRs and Rule 144A GDRs. While the Regulation S and Rule 144A GDR programmes are expected to remain in place following the delisting of the GDRs, holders of Regulation S and Rule 144A GDRs will no longer be able to trade their GDRs on the LSE. However, holders of Regulation S and Rule 144A GDRs will continue to own their GDRs and will retain the rights attached to such GDRs, including the right to vote the underlying shares in accordance with the terms and conditions of the deposit agreement. While it is possible that an over-the-counter market for the GDRs could develop following the delisting, no assurance can be given that it will develop.

For further information, please contact: Investor Relations: email: ir@eastpharma.com

Cautionary Statement Regarding Forward Looking Statements

Some of the information in this document may contain or refer to projections or other forward-looking statements regarding future events or the future financial performance of the Company. You can identify forward looking statements by terms such as “expect”, “believe”, “anticipate”, “estimate”, “forecast”, “intend”, “will”, “could”, “may”, or “might” the negative of such terms or other similar expressions. The Company wishes to caution you that these statements are only predictions and are based upon various assumptions which are inherently subject to significant uncertainties and contingencies which are difficult or impossible to predict and are beyond our control. We may not achieve or accomplish these plans or predictions. The Company does not necessarily intend to update these statements to reflect events and circumstances occurring after the date hereof or to reflect the occurrence of unanticipated events. Many factors could cause the actual results to differ materially from those contained in projections or forward-looking statements of the Company, including, among others, general economic conditions, the competitive environment, rapid technological and market change in the industries in which the Company operates, as well as many other risks specifically related to the Company and its business and operations.

Statement Regarding Inside Information

This announcement contains inside information. The subject matter, the identity of the issuer, the identity of the persons making the notification and their titles, and the date and time of the notification are all as set forth above.

Important Notice

THE RELEASE, PUBLICATION OR DISTRIBUTION OF THIS ANNOUNCEMENT IN JURISDICTIONS OTHER THAN THE UNITED KINGDOM MAY BE RESTRICTED BY LAW AND THEREFORE ANY PERSONS WHO ARE SUBJECT TO THE LAWS OF ANY JURISDICTION OTHER THAN THE UNITED KINGDOM SHOULD INFORM THEMSELVES ABOUT, AND OBSERVE, ANY APPLICABLE REQUIREMENTS. THIS ANNOUNCEMENT HAS BEEN PREPARED FOR THE PURPOSES OF COMPLYING WITH ENGLISH LAW AND THE INFORMATION DISCLOSED MAY NOT BE THE SAME AS THAT WHICH WOULD HAVE BEEN DISCLOSED IF THIS ANNOUNCEMENT HAD BEEN PREPARED IN ACCORDANCE WITH THE LAWS AND REGULATIONS OF ANY JURISDICTION OUTSIDE OF ENGLAND.

THE RELEASE, PUBLICATION OR DISTRIBUTION OF THIS ANNOUNCEMENT IN JURISDICTIONS MAY BE RESTRICTED BY LAW AND THEREFORE PERSONS SHOULD INFORM THEMSELVES ABOUT THE LAWS OF THEIR JURISDICTION AND OBSERVE ANY APPLICABLE REQUIREMENTS.

EastPharma Ltd - a company active in the manufacturing and marketing of pharmaceutical products in Turkey and in other regional markets; for further information please visit www.eastpharma.com.